PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Blind Loop Syndrome”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed2006

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.

BACKGROUND: Alterations in gut flora may be important in the pathophysiology of the irritable bowel syndrome (IBS). OBJECTIVE: To determine whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS. DESIGN: Double-blind, randomized, placebo-controlled study. SETTING: 2 tertiary care medical centers. PARTICIPANTS: 87 patients who met Rome I criteria for IBS and were enrolled from December 2003 to March 2005. INTERVENTIONS: Participants who met enrollment criteria were randomly assigned to receive 400 mg of rifaximin 3 times daily for 10 days (n = 43) or placebo (n = 44). Eighty participants completed rifaximin therapy or placebo, and follow-up data were available for at least 34 participants per study group at any time point thereafter. MEASUREMENTS: A questionnaire was administered before treatment and 7 days after treatment. The primary outcome was global improvement in IBS. Patients were then asked to keep a weekly symptom diary for 10 weeks. RESULTS: Over the 10 weeks of follow-up, rifaximin resulted in greater improvement in IBS symptoms (P = 0.020). In addition, rifaximin recipients had a lower bloating score after treatment. LIMITATIONS: The major limitations of the study were its modest sample size and short duration and that most patients were from 1 center. CONCLUSIONS: Rifaximin improves IBS symptoms for up to 10 weeks after the discontinuation of therapy.

Adolescent↗
PubMed1975

[Pathophysiologic significance of small intestine flora in the stagnant loop syndrome].

A report is given about a 53 years old man with a "stagnant loop syndrome" associated with a diverticulosis of the whole small intestine and colon. Steatorrhoea was the main clinical symptom. The classification, distribution and frequency of intestinal diverticulosis is based on radiological results. The pathological values of the absorption tests prompted for a discussion of new examinations in the "stagnant loop syndrome". The property of the intestinal bacteria to influence the absorption of fat, xylose and vitamin B12 is stressed. Finally the possible methods of treating the diverticulosis with "stagnant loop syndrome" are discussed.

Bacterial Physiological Phenomena↗
PubMed1994

[Formation of a blind loop: an unusual bleeding site in chronic intestinal hemorrhage].

The blind-pouch-syndrome may display a variety of symptoms. But it rarely causes intestinal bleeding. In a patient suffering from anemia of chronic intestinal hemorrhage, a blind-pouch was diagnosed through the search for colon polyps. A hemicolectomy with a side-to-side ileocolic anastomosis was performed 30 years ago, but there were no symptoms of maldigestion or malabsorption. The explorative laparotomy revealed an anastomotic stricture with a lot of coproliths in the ileum-blind-pouch. The histological examination of the resected anastomosis showed an unspecific inflammation of the mucosa. Excluding other potential causes of intestinal hemorrhage, this mucosal irritation was presumed to be the bleeding site.

Adenoma, Villous↗
PubMed1986

Potential hazards of hypochlorhydria in the treatment of peptic ulcer.

The introduction of ulcer-healing drugs that do not induce hypochlorhydria--the main aim of therapy thus far--has led to the consideration of the possible disadvantages of acid secretion inhibition. Potential dangers are that micro-organisms destroyed by the normal stomach survive and proliferate in the stomach and small intestine. The incidence of gastric cancer is higher in pernicious anemia and after partial gastrectomy. It has been suggested that the intragastric bacteria may convert dietary nitrate into nitrite that may then be nitrosated to carcinogenic N-nitroso compounds. The third potential hazard is the development of stagnant loop syndrome in patients treated with H2 antagonists. In a double-blind randomised trial of colloidal bismuth subcitrate (CBS) versus cimetidine in duodenal ulcer, gastric juice was aspirated for pH measurement. There was a significant increase in the total number of bacteria isolated during cimetidine treatment (P less than 0.01) and an increase in nitrate-reducing organisms (P less than 0.05), but no change in the CBS group. It is concluded that there may be advantages in using ulcer-healing drugs that do not reduce H+ concentration.

Blind Loop Syndrome↗